Topic
Drug Labeling
96 published works
Health Industry Washington Watch
Hundreds of Drugs and Biologics Face Labeling Changes under New FDA Plan
In a notice published in the Federal Register on May 7, 2014, the U.S. Food and Drug Administration (“FDA”) announced its intent to incentivize manufacturers to voluntarily update their prescription…
Louisiana Law Blog
Louisiana Fourth Circuit Offers Clarification on the Role of Pharmaceutical Labeling and Package Inserts in Medical Malpractice Litigation: Deviation from manufacturer dosage instructions is not ipso facto evidence of breach
The effect of a physician’s decision to deviate from the pharmaceutical company’s dosage instructions contained in a drug’s FDA approved package insert has been a recurring issue in medical malpractice…
Dangerous Drugs & Medical Devices
Our Comment in Support of the FDA’s Proposed Rule: Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products (78 Fed. Reg. 67985)
Janice L. WeinerCenter for Drug Evaluation and ResearchFood and Drug Administration10903 New Hampshire Ave.Bldg. 51, Room 6304Silver Spring, MD 20993-0002 Dear Ms. Weiner, We are grateful for the opportunity to…
Focus on Regulation
FDA Proposes Rule Affecting Liability for Generic Drug Manufacturers
By Robert Church, Lauren Colton, Jason F. Conaty
On Wednesday, November 13, 2013, the Food and Drug Administration (FDA) issued a proposed rule under which generic drug manufacturers would be able to independently update the safety information accompanying…
DEA Chronicles
Changes Ahead: New Rules for Painkillers
FDA Announces New Labeling and Postmarket Studies Requirements for Painkillers On September 10, 2013, the FDA announced its plan to issue new regulations for labeling extended-release and long-acting (ER/LA) opioid analgesics…
Defense Litigation Insider
Massachusetts Court Finds Plaintiffs’ Claims Against Generic Drug Manufacturers Are Barred By Preemption
Written by Jonathan F. Tabasky and Kate B. Puccio Massachusetts Superior Court Judge Bruce R. Henry recently dismissed a series of claims against several manufacturers of the generic drug Metoclopramide…
Drug & Device Law
Revisiting Publisher (Non)Liability
By Bexis
We were perusing the recent GAO report on electronic drug labeling in our spare time (we’re weird like that). We found a number of interesting points − such as what…
Mass Tort Defense
Supreme Court Issues Important Preemption Ruling
By Sean Wajert
The Supreme Court last week reversed the First Circuit decision in Mutual Pharmaceutical Co. v. Bartlett, No. 12-142 (U.S., 6/24/13). Readers will rec
Health Care and Life Sciences
Title III Healthcare News: Access Board Announces First Meeting of Working Group on Accessible Drug Labels
By Kristina M. Launey As noted during our Healthcare webinar last week, the accessibility of drug labels accessible is on the Administration’s agenda. Yesterday the Access Board announced that the stakeholder…
Drug & Device Law
Interesting Mensing Application
By Bexis
We saw the 360 blurb this morning on In re Darvocet, Darvon & Propoxyphene Products Liability Litigation, MDL Docket No. 2226, slip op. (E.D. Ky. Oct. 10, 2012), and we…